IP Library Granted Patent US 8,895,727
Granted Patent B2
US 8,895,727 · App. 14/087,537 · Granted Nov 25, 2014

Method for preparation of fluorine-18-labeled flumazenil using diaryliodonium salt precursor

Inventors: Byung Chul Lee (Seoul, KR); Byung Seok Moon (Gyeonggi-Do, KR); Ji Sun Kim (Gyeonggi-do, KR)
Assignee: Bio Imaging Korea Co., Ltd.
C07D487/04A61K31/5517
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,727
App. No.
14/087,537
Granted
Nov 25, 2014
Kind
B2
Abstract

Disclosed is the synthesis of [ 18 F]flumazenil that is useful in imaging epileptic lesions by PET (positron emission tomography). A method for preparing [ 18 F]flumazenil by reacting a diaryliodonium salt precursor with the positron-emitting radionuclide fluorine-18. [ 18 F]flumazenil can be prepared from the diaryliodonium salt precursor in the presence of kryptofix 2.2.2. /potassium carbonate(K 2.2.2. /K 2 CO 3 ) and TEMPO in dimethylformamide (DMF) at a high yield.

Claims (8)

1. A method for preparing fluorine-18-labeled flumazenil, comprising reacting a diaryliodonium salt precursor with fluorine-18 at 130 to 160° C. in the presence of a phase transition catalyst which is selected from the group consisting of kryptofix 2.2.2. /potassium carbonate (K 2.2.2. /K 2 CO 3 ), tetrabutylammonium hydroxide (TBAOH), tetrabutylammonium bicarbonate (TBAHCO 3 ), cesium hydroxide (CsOH), and a combination thereof,

wherein the diaryliodonium salt precursor is represented by the following Chemical Formula 1:

wherein Ar− is selected from the group consisting of the following aryl (Ar−) radicals:

and X − is selected from among trifluoromethane sulfonate), perfluoro C 2 -C 10 alkyl sulphonate, trifluoroacetate, tetraphenylborate), toluene sulfonate), Br − , and Cl − .

2. The method of claim 1 , wherein the reacting is carried out in the presence of 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) in a reaction solvent.

3. A method for preparing fluorine-18-labeled flumazenil, comprising reacting a diaryliodonium salt precursor with fluorine-18, wherein the diaryliodonium salt precursor is represented by the following Chemical Formula 2:

wherein —Ar is

R 1 ˜R 3 independently selected from among H, C 1 alkyl, C 2 alkyl, C 1 haloalkyl, and C 2 haloalkyl, and X − is selected from among trifluoromethane sulfonate, perfluoro C 2 -C 10 alkyl sulphonate, trifluoroacetate, tetraphenylborate, toluene sulfonate, Br − , and Cl − .

Assignments (2)
CHANGE OF NAME Recorded Jun 18, 2020
From: BIO IMAGING KOREA CO., LTD.
To: BIK THERAPEUTICS INC.
Reel/Frame 052974/0871 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2013
From: LEE, BYUNG CHUL; MOON, BYUNG SEOK; KIM, JI SUN
To: BIO IMAGING KOREA CO., LTD.
Reel/Frame 031659/0684 →
Priority Claims (1)
KR 10-2011-0049726 · May 25, 2011 · national
Continuity (2)
Continuation PCTKR2011004075 · Jun 3, 2011
Related Publication 20140081018A1 · Mar 20, 2014